                                                    Concept  PeriodEnd                                                                                                                                                                                                                         Dims        Value
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 5.381600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 5.091400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 9.179300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.423000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.058000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 8.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:ProductMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 1.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:ProductMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 2.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:ProductMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 4.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:RoyaltyMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 9.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:RoyaltyMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 6.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:RoyaltyMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 6.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                            srt:ProductOrServiceAxis:pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 4.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.423000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.058000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 8.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                            srt:ProductOrServiceAxis:pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 4.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                            srt:ProductOrServiceAxis:pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 4.420000e+08
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                                                              6.362700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                                                              5.955300e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                                                              1.011750e+11
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                   us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:HaleonMember 1.425200e+10
                                           us-gaap:Revenues 2023-09-30                                                                                                                                                   us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:HaleonMember 1.392100e+10
                                           us-gaap:Revenues 2022-09-30                                                                                                                               us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:ConsumerHealthcareJVHaleonMember 1.356600e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                    us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:ViivHealthcareLimitedMember 8.971000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                    us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:ViivHealthcareLimitedMember 7.845000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                                                    us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:ViivHealthcareLimitedMember 6.955000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                         us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 9.486000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                         us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 8.400000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                         us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 9.588000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.240000e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.823700e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.982600e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 1.228000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 1.316000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 1.349000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                                                              6.362700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                                                              5.955300e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                                                              1.011750e+11
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.240000e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.823700e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.982600e+10
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.353000e+09
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.122000e+10
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.780900e+10
                                           us-gaap:Revenues 2024-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.716000e+09
                                           us-gaap:Revenues 2023-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.279000e+09
                                           us-gaap:Revenues 2022-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.893300e+10
                                           us-gaap:Revenues 2024-12-31                                          us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ExcludingComirnatyAndPaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.133100e+10
                                           us-gaap:Revenues 2023-12-31                                          us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ExcludingComirnatyAndPaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.573800e+10
                                           us-gaap:Revenues 2022-12-31                                          us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ExcludingComirnatyAndPaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.308400e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 3.869100e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 2.814500e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 4.331700e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 1.605700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 2.091000e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 4.053400e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 8.879000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 1.049800e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 1.732400e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                                                              6.362700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                                                              5.955300e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                                                              1.011750e+11
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                                                              6.362700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                                                              5.955300e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                                                              1.011750e+11
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.240000e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.823700e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.982600e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.013500e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.079900e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.318100e+10
                                           us-gaap:Revenues 2024-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.366000e+09
                                           us-gaap:Revenues 2023-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.747000e+09
                                           us-gaap:Revenues 2022-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.480000e+09
                                           us-gaap:Revenues 2024-12-31                                                  us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.411000e+09
                                           us-gaap:Revenues 2023-12-31                                                  us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.501000e+09
                                           us-gaap:Revenues 2022-12-31                                                  us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.342000e+09
                                           us-gaap:Revenues 2024-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.716000e+09
                                           us-gaap:Revenues 2023-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.279000e+09
                                           us-gaap:Revenues 2022-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.893300e+10
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.353000e+09
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.122000e+10
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.780900e+10
                                           us-gaap:Revenues 2024-12-31                                                        us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.263000e+09
                                           us-gaap:Revenues 2023-12-31                                                        us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.280000e+08
                                           us-gaap:Revenues 2022-12-31                                                        us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.130000e+08
                                           us-gaap:Revenues 2024-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.550000e+08
                                           us-gaap:Revenues 2023-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.900000e+08
                                           us-gaap:Revenues 2024-12-31                                                         us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PremarinFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.800000e+08
                                           us-gaap:Revenues 2023-12-31                                                         us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PremarinFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.970000e+08
                                           us-gaap:Revenues 2022-12-31                                                         us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PremarinFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.550000e+08
                                           us-gaap:Revenues 2024-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:BMP2Member; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.520000e+08
                                           us-gaap:Revenues 2023-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:BMP2Member; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.380000e+08
                                           us-gaap:Revenues 2022-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:BMP2Member; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.770000e+08
                                           us-gaap:Revenues 2024-12-31                                                       us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.800000e+08
                                           us-gaap:Revenues 2023-12-31                                                       us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.680000e+08
                                           us-gaap:Revenues 2022-12-31                                                       us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.000000e+08
                                           us-gaap:Revenues 2024-12-31                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.259000e+09
                                           us-gaap:Revenues 2023-12-31                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.233000e+09
                                           us-gaap:Revenues 2022-12-31                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.473000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.665200e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.498800e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.385100e+10
                                           us-gaap:Revenues 2024-12-31                                                             us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.451000e+09
                                           us-gaap:Revenues 2023-12-31                                                             us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.321000e+09
                                           us-gaap:Revenues 2022-12-31                                                             us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.447000e+09
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.168000e+09
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.703000e+09
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.796000e+09
                                           us-gaap:Revenues 2024-12-31                                                               us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.900000e+08
                                           us-gaap:Revenues 2023-12-31                                                               us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.300000e+08
                                           us-gaap:Revenues 2022-12-31                                                               us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.003000e+09
                                           us-gaap:Revenues 2024-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.370000e+08
                                           us-gaap:Revenues 2023-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.570000e+08
                                           us-gaap:Revenues 2022-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.860000e+08
                                           us-gaap:Revenues 2024-12-31                                                            us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.860000e+08
                                           us-gaap:Revenues 2023-12-31                                                            us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.110000e+08
                                           us-gaap:Revenues 2022-12-31                                                            us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.120000e+08
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.090000e+08
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.450000e+08
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.860000e+08
                                           us-gaap:Revenues 2024-12-31                                                     us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:InflectraRemsimaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.090000e+08
                                           us-gaap:Revenues 2023-12-31                                                     us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:InflectraRemsimaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.900000e+08
                                           us-gaap:Revenues 2022-12-31                                                     us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:InflectraRemsimaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.320000e+08
                                           us-gaap:Revenues 2024-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.800000e+08
                                           us-gaap:Revenues 2023-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.060000e+08
                                           us-gaap:Revenues 2022-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.310000e+08
                                           us-gaap:Revenues 2024-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.700000e+08
                                           us-gaap:Revenues 2023-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.390000e+08
                                           us-gaap:Revenues 2022-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.600000e+08
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:BeneFIXMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.810000e+08
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:BeneFIXMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.240000e+08
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:BeneFIXMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.250000e+08
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.150000e+08
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.280000e+08
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.700000e+07
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OxbrytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.010000e+08
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OxbrytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.280000e+08
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OxbrytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.300000e+07
                                           us-gaap:Revenues 2024-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.448000e+09
                                           us-gaap:Revenues 2023-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.514000e+09
                                           us-gaap:Revenues 2022-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.730000e+09
                                           us-gaap:Revenues 2024-12-31                                                   us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.070000e+08
                                           us-gaap:Revenues 2023-12-31                                                   us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.920000e+08
                                           us-gaap:Revenues 2022-12-31                                                   us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.430000e+08
                                           us-gaap:Revenues 2024-12-31                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.561200e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.245000e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.279400e+10
                                           us-gaap:Revenues 2024-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.367000e+09
                                           us-gaap:Revenues 2023-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.753000e+09
                                           us-gaap:Revenues 2022-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.120000e+09
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.039000e+09
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.659000e+09
                                           us-gaap:Revenues 2022-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.650000e+09
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.588000e+09
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.300000e+07
                                           us-gaap:Revenues 2024-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.089000e+09
                                           us-gaap:Revenues 2023-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.600000e+07
                                           us-gaap:Revenues 2024-12-31                                                       us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.037000e+09
                                           us-gaap:Revenues 2023-12-31                                                       us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.407000e+09
                                           us-gaap:Revenues 2022-12-31                                                       us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.753000e+09
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.780000e+08
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.036000e+09
                                           us-gaap:Revenues 2022-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.003000e+09
                                           us-gaap:Revenues 2024-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.310000e+08
                                           us-gaap:Revenues 2023-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.390000e+08
                                           us-gaap:Revenues 2022-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.430000e+08
                                           us-gaap:Revenues 2024-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.450000e+08
                                           us-gaap:Revenues 2023-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.450000e+08
                                           us-gaap:Revenues 2022-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.750000e+08
                                           us-gaap:Revenues 2024-12-31                                                           us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.070000e+08
                                           us-gaap:Revenues 2023-12-31                                                           us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.770000e+08
                                           us-gaap:Revenues 2022-12-31                                                           us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.560000e+08
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.800000e+08
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.800000e+07
                                           us-gaap:Revenues 2024-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.330000e+08
                                           us-gaap:Revenues 2023-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.000000e+07
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.310000e+08
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.000000e+06
                                           us-gaap:Revenues 2024-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.170000e+08
                                           us-gaap:Revenues 2023-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.400000e+07
                                           us-gaap:Revenues 2022-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.800000e+07
                                           us-gaap:Revenues 2024-12-31                                                     us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.670000e+09
                                           us-gaap:Revenues 2023-12-31                                                     us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.729000e+09
                                           us-gaap:Revenues 2022-12-31                                                     us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.846000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 1.146000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 1.272000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 1.342000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 8.200000e+07
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 4.400000e+07
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 7.000000e+06
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.240000e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.823700e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.982600e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 2.676500e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 1.929900e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 3.433700e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                         us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:OncologyDivisionMember 1.156700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                         us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:OncologyDivisionMember 8.450000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                         us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:OncologyDivisionMember 8.583000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 2.406800e+10
                                           us-gaap:Revenues 2023-12-31                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 3.048800e+10
                                           us-gaap:Revenues 2022-12-31                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 5.690500e+10
                                           us-gaap:Revenues 2024-12-31 us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:CounterpartyNameAxis:pfe:CommercializationPartnerMember; srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 1.195400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 1.087100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 2.324800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 2.331400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 4.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 3.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 7.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 6.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 4.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 3.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 7.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 6.080000e+08
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                                                              1.465300e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                                                              1.328300e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                                                              2.836700e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                                                              2.816200e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.430500e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.299100e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 3.480000e+08
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 2.920000e+08
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                                                              1.465300e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                                                              1.328300e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.774600e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.759500e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 6.220000e+08
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 5.670000e+08
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                                                              2.836700e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                                                              2.816200e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.430500e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.299100e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.774600e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.759500e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 8.894000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 7.892000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 1.726800e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 1.740600e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 3.393000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 3.164000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 6.571000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 6.362000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 2.366000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 2.227000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 4.529000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 4.394000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                                                              1.465300e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                                                              1.328300e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                                                              2.836700e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                                                              2.816200e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                                                              1.465300e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                                                              1.328300e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                                                                              2.836700e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                                                                              2.816200e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.430500e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.299100e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.774600e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.759500e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.540000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.952000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.123600e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.216300e+10
                                           us-gaap:Revenues 2025-06-29                                                                srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.003000e+09
                                           us-gaap:Revenues 2024-06-30                                                                srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.877000e+09
                                           us-gaap:Revenues 2025-06-29                                                                srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.926000e+09
                                           us-gaap:Revenues 2024-06-30                                                                srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.917000e+09
                                           us-gaap:Revenues 2025-06-29                                                  srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.383000e+09
                                           us-gaap:Revenues 2024-06-30                                                  srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.359000e+09
                                           us-gaap:Revenues 2025-06-29                                                  srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.043000e+09
                                           us-gaap:Revenues 2024-06-30                                                  srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.050000e+09
                                           us-gaap:Revenues 2025-06-29                                                              srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.810000e+08
                                           us-gaap:Revenues 2024-06-30                                                              srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.950000e+08
                                           us-gaap:Revenues 2025-06-29                                                              srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.450000e+08
                                           us-gaap:Revenues 2024-06-30                                                              srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.480000e+08
                                           us-gaap:Revenues 2025-06-29                                                     srt:ProductOrServiceAxis:pfe:PaxlovidEUALabeledMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.270000e+08
                                           us-gaap:Revenues 2024-06-30                                                     srt:ProductOrServiceAxis:pfe:PaxlovidEUALabeledMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.510000e+08
                                           us-gaap:Revenues 2025-06-29                                                     srt:ProductOrServiceAxis:pfe:PaxlovidEUALabeledMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.180000e+08
                                           us-gaap:Revenues 2024-06-30                                                     srt:ProductOrServiceAxis:pfe:PaxlovidEUALabeledMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.286000e+09
                                           us-gaap:Revenues 2025-06-29                                                        srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.590000e+08
                                           us-gaap:Revenues 2024-06-30                                                        srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.560000e+08
                                           us-gaap:Revenues 2025-06-29                                                        srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.070000e+08
                                           us-gaap:Revenues 2024-06-30                                                        srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.330000e+08
                                           us-gaap:Revenues 2025-06-29                                                                srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.430000e+08
                                           us-gaap:Revenues 2024-06-30                                                                srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.600000e+07
                                           us-gaap:Revenues 2025-06-29                                                                srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.740000e+08
                                           us-gaap:Revenues 2024-06-30                                                                srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.010000e+08
                                           us-gaap:Revenues 2025-06-29                                                       srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.090000e+08
                                           us-gaap:Revenues 2024-06-30                                                       srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.000000e+08
                                           us-gaap:Revenues 2025-06-29                                                       srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.720000e+08
                                           us-gaap:Revenues 2024-06-30                                                       srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.650000e+08
                                           us-gaap:Revenues 2025-06-29                                               srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.360000e+08
                                           us-gaap:Revenues 2024-06-30                                               srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.590000e+08
                                           us-gaap:Revenues 2025-06-29                                               srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.350000e+09
                                           us-gaap:Revenues 2024-06-30                                               srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.463000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.378000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.083000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.364000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.926000e+09
                                           us-gaap:Revenues 2025-06-29                                                             srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.615000e+09
                                           us-gaap:Revenues 2024-06-30                                                             srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.323000e+09
                                           us-gaap:Revenues 2025-06-29                                                             srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.101000e+09
                                           us-gaap:Revenues 2024-06-30                                                             srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.460000e+09
                                           us-gaap:Revenues 2025-06-29                                                              srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.220000e+08
                                           us-gaap:Revenues 2024-06-30                                                              srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.030000e+08
                                           us-gaap:Revenues 2025-06-29                                                              srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.500000e+08
                                           us-gaap:Revenues 2024-06-30                                                              srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.970000e+08
                                           us-gaap:Revenues 2025-06-29                                                           srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.660000e+08
                                           us-gaap:Revenues 2024-06-30                                                           srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.440000e+08
                                           us-gaap:Revenues 2025-06-29                                                           srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.300000e+08
                                           us-gaap:Revenues 2024-06-30                                                           srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.110000e+08
                                           us-gaap:Revenues 2025-06-29                                                            srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.630000e+08
                                           us-gaap:Revenues 2024-06-30                                                            srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.500000e+08
                                           us-gaap:Revenues 2025-06-29                                                            srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.990000e+08
                                           us-gaap:Revenues 2024-06-30                                                            srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.750000e+08
                                           us-gaap:Revenues 2025-06-29                                                               srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.540000e+08
                                           us-gaap:Revenues 2024-06-30                                                               srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.790000e+08
                                           us-gaap:Revenues 2025-06-29                                                               srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.940000e+08
                                           us-gaap:Revenues 2024-06-30                                                               srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.380000e+08
                                           us-gaap:Revenues 2025-06-29                                                            srt:ProductOrServiceAxis:pfe:InflectraMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.390000e+08
                                           us-gaap:Revenues 2024-06-30                                                            srt:ProductOrServiceAxis:pfe:InflectraMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.700000e+07
                                           us-gaap:Revenues 2025-06-29                                                            srt:ProductOrServiceAxis:pfe:InflectraMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.910000e+08
                                           us-gaap:Revenues 2024-06-30                                                            srt:ProductOrServiceAxis:pfe:InflectraMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.550000e+08
                                           us-gaap:Revenues 2025-06-29                                                        srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.600000e+07
                                           us-gaap:Revenues 2024-06-30                                                        srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.400000e+07
                                           us-gaap:Revenues 2025-06-29                                                        srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.130000e+08
                                           us-gaap:Revenues 2024-06-30                                                        srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.740000e+08
                                           us-gaap:Revenues 2025-06-29                                                           srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.060000e+08
                                           us-gaap:Revenues 2024-06-30                                                           srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.190000e+08
                                           us-gaap:Revenues 2025-06-29                                                           srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.010000e+08
                                           us-gaap:Revenues 2024-06-30                                                           srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.390000e+08
                                           us-gaap:Revenues 2025-06-29                                                             srt:ProductOrServiceAxis:pfe:CresembaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.110000e+08
                                           us-gaap:Revenues 2024-06-30                                                             srt:ProductOrServiceAxis:pfe:CresembaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.100000e+07
                                           us-gaap:Revenues 2025-06-29                                                             srt:ProductOrServiceAxis:pfe:CresembaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.840000e+08
                                           us-gaap:Revenues 2024-06-30                                                             srt:ProductOrServiceAxis:pfe:CresembaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.460000e+08
                                           us-gaap:Revenues 2025-06-29                                                              srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.900000e+07
                                           us-gaap:Revenues 2024-06-30                                                              srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.700000e+07
                                           us-gaap:Revenues 2025-06-29                                                              srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.270000e+08
                                           us-gaap:Revenues 2024-06-30                                                              srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.900000e+07
                                           us-gaap:Revenues 2025-06-29                                                        srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.087000e+09
                                           us-gaap:Revenues 2024-06-30                                                        srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.146000e+09
                                           us-gaap:Revenues 2025-06-29                                                        srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.170000e+09
                                           us-gaap:Revenues 2024-06-30                                                        srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.221000e+09
                                           us-gaap:Revenues 2025-06-29                                                   srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.900000e+08
                                           us-gaap:Revenues 2024-06-30                                                   srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.290000e+08
                                           us-gaap:Revenues 2025-06-29                                                   srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.050000e+08
                                           us-gaap:Revenues 2024-06-30                                                   srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.210000e+08
                                           us-gaap:Revenues 2025-06-29                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.387000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.956000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.145000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.505000e+09
                                           us-gaap:Revenues 2025-06-29                                                                   srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.049000e+09
                                           us-gaap:Revenues 2024-06-30                                                                   srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.130000e+09
                                           us-gaap:Revenues 2025-06-29                                                                   srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.026000e+09
                                           us-gaap:Revenues 2024-06-30                                                                   srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.184000e+09
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.660000e+08
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.950000e+08
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.023000e+09
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.130000e+08
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.420000e+08
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.940000e+08
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.670000e+08
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.350000e+08
                                           us-gaap:Revenues 2025-06-29                                                       srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.530000e+08
                                           us-gaap:Revenues 2024-06-30                                                       srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.790000e+08
                                           us-gaap:Revenues 2025-06-29                                                       srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.170000e+08
                                           us-gaap:Revenues 2024-06-30                                                       srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.430000e+08
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.510000e+08
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.690000e+08
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.730000e+08
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.320000e+08
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.550000e+08
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.790000e+08
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.720000e+08
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.360000e+08
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.430000e+08
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.520000e+08
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.620000e+08
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.890000e+08
                                           us-gaap:Revenues 2025-06-29                                                           srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.820000e+08
                                           us-gaap:Revenues 2024-06-30                                                           srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.480000e+08
                                           us-gaap:Revenues 2025-06-29                                                           srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.170000e+08
                                           us-gaap:Revenues 2024-06-30                                                           srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.640000e+08
                                           us-gaap:Revenues 2025-06-29                                                                   srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.490000e+08
                                           us-gaap:Revenues 2024-06-30                                                                   srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.670000e+08
                                           us-gaap:Revenues 2025-06-29                                                                   srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.000000e+08
                                           us-gaap:Revenues 2024-06-30                                                                   srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.130000e+08
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.320000e+08
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.210000e+08
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.340000e+08
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.270000e+08
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:AromasinMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.110000e+08
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:AromasinMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.700000e+07
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:AromasinMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.190000e+08
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:AromasinMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.700000e+08
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.500000e+07
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.200000e+07
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.450000e+08
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.500000e+07
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.600000e+07
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.200000e+07
                                           us-gaap:Revenues 2025-06-29                                                                  srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.600000e+07
                                           us-gaap:Revenues 2024-06-30                                                                  srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.500000e+07
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.600000e+07
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.300000e+07
                                           us-gaap:Revenues 2025-06-29                                                                    srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.900000e+07
                                           us-gaap:Revenues 2024-06-30                                                                    srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.000000e+07
                                           us-gaap:Revenues 2025-06-29                                                     srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.800000e+08
                                           us-gaap:Revenues 2024-06-30                                                     srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.470000e+08
                                           us-gaap:Revenues 2025-06-29                                                     srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.250000e+08
                                           us-gaap:Revenues 2024-06-30                                                     srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.480000e+08
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 3.280000e+08
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 2.780000e+08
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 5.850000e+08
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 5.350000e+08
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 2.000000e+07
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 1.500000e+07
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 3.700000e+07
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 3.200000e+07
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.430500e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.299100e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.774600e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.759500e+10
                                           us-gaap:Revenues 2025-06-29                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 8.793000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 7.828000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 1.707800e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 1.725400e+10
                                           us-gaap:Revenues 2025-06-29                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 5.512000e+09
                                           us-gaap:Revenues 2024-06-30                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 5.163000e+09
                                           us-gaap:Revenues 2025-06-29                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 1.066800e+10
                                           us-gaap:Revenues 2024-06-30                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 1.034100e+10